<DOC>
	<DOCNO>NCT00423709</DOCNO>
	<brief_summary>1 . To determine feasibility toxicity employ allogeneic peripheral blood stem cell transplantation intensive non-myeloablative chemotherapy patient relapse Hodgkin 's disease ( HD ) . 2 . To determine engraftment kinetics degree chimerism achieve strategy . 3 . To assess antitumor activity approach high-risk HD patient possible presence graft-vs-HD effect .</brief_summary>
	<brief_title>Allogeneic Blood Stem Cell Transplantation</brief_title>
	<detailed_description>All patient study must plastic tube ( catheter ) insert vein collarbone . Drugs stem cell give tube . Fludarabine give catheter day four day . Patients also receive melphalan two day catheter . Patients receive transplant match unrelated donor ( i.e . blood relative ) mismatch related donor ( i.e . blood relative , full match ) also receive antithymocyte globulin ( ATG ) day three day . ATG help prevent graft-versus-host disease . All patient expect need blood transfusion part treatment . Beginning two day transplant , tacrolimus give catheter . It give 24 hour day patient swallow . The patient swallow one tacrolimus pill day 6 month . On transplant day ( `` day 0 '' ) , stem cell bone marrow obtain donor infuse catheter ( `` transplant '' ) . Drugs give reduce chance allergic reaction . Starting day 7 transplant , filgrastim give needle increase growth white blood cell . Methotrexate give IV day 1,3,6 , 11 transplant . The patient may require blood transfusion follow 2-4 week sometimes longer . Patients progressive ( `` grow '' ) Hodgkin 's disease transplant initially take immunosuppressive medication ( tacrolimus , corticosteroid ) . If response maneuver , consider infusion additional cell donor , without precede chemotherapy Both maneuver may produce response ( `` shrinkage '' ) tumor . Patients persistent stable ( `` grow '' ) disease may also treat similar fashion . Potential side effect infusion additional cell include graft-versus-host disease /or generalize drop blood count . Both condition serious life-threatening . Blood , urine , bone marrow x-ray examination perform necessary monitor result bone marrow transplantation . Patients may require blood platelet transfusion . Blood test do daily hospitalize several time week blood count recover . Bone marrow aspiration biopsy perform prior transplant , donate cell show sign engraftment , time next 1 3 year evaluate growth transplant marrow , evaluate possible recurrence malignancy recovery immunity . This investigational study . Up 50 patient treat study . If initial result discourage , study may stop minimum four patient enrol .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Patients &lt; 65 year age histologically confirm primary refractory relapse Hodgkin 's disease . In event transplant unrelated donor , upper age limit 55 year . 2 . Patients fail relapse autologous transplant eligible . 3 . Patients responsive stable disease salvage chemotherapy . Patients untreated , smolder ( i.e . rapidly progressive ) relapse eligible . Patients fail relapse autologous transplant eligible . 4 . Patients must serum bilirubin &lt; 2.0 mg/dl , serum creatinine &lt; 2.0 mg/dl , symptomatic cardiac pulmonary disease PS &lt; 2 . Life expectancy severely limited concomitant illness ( &gt; 12 week ) . Left ventricular ejection fraction &gt; 50 % . 5 . Patients must HLAcompatible donor ( oneantigen mismatch related donor acceptable ) willing donate marrow rhGCSFmobilized peripheral blood stem cell . In event transplant unrelated donor , fully serologically A , B DRmatched donor ( include donor single micromismatch DR/DQ molecular typing ) acceptable . HLAcompatible cord blood unit also acceptable recipient body weight 50 kg less . 1 . Patients documented disease progression salvage chemotherapy eligible . 2 . Uncontrolled arrhythmia symptomatic cardiac disease . FEV1 , FVC DLCO le 50 % . Symptomatic pulmonary disease . Evidence chronic active hepatitis cirrhosis . 3 . Active uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Allogeneic Blood Stem Cell Transplantation</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Melphalan</keyword>
</DOC>